Ischemix Advancing Ischemia-Reperfusion Therapy

Our name

"Ischemix" (pronounced
iss-KEY-mix) is based on
the word "ischemia" which describes the medical condition of insufficient blood flow or nutrition to living cells or organs of the body. The word has a Greek origin;
isch- means restriction, hema or haema refers to blood.

Ischemix is developing
drugs to protect against the damaging effects associated with ischemia in the heart, brain, and other organs.

What is Ischemia-Reperfusion Injury?

clotA heart attack is usually caused by blockage of an artery supplying the heart. Muscle cells beyond the block are then deprived of oxygen and nutrients. This ischemia leads to cell death- "myocardial infarction"-- which may be fatal.

Cardiac surgeries and interventional procedures to restore blood flow may temporarily increase ischemia, and paradoxically result in "reperfusion injury" which can exceed the original ischemic damage. Thus the sequence of events is known as "ischemia-reperfusion" injury. This leads to extended hospital stay and limits recovery in patients undergoing cardiac surgeries and interventional procedures. Such complications add thousands to hospital costs.

Read more about ischemia-reperfusion
injury and therapy

About Ischemix

microscopeIschemix is a privately-held clinical phase company developing drugs to reduce cell and organ damage associated with ischemia-reperfusion injury. The Company's leading compound is a unique dual-function molecule. The first stage of human clinical trials of this compound has been completed. Ischemix is poised for proof-of-principle studies in prevention of adverse events in patients undergoing a cardiac interventional procedure.

Learn more about Ischemix